Ipsen's Elafibranor Trial: Strategic Implications in Rare Liver Disease Market
Hepatology · Rare Disease • Trial Update • Jul 3, 2026
Assessment confidence: 87% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
Executive Thesis
The initiation of Ipsen's trial for elafibranor in Primary Sclerosing Cholangitis represents a significant step in addressing an unmet medical need in a rare disease area. Successful trial outcomes could enhance Ipsen's position in hepatology and disrupt the competitive landscape among companies focused on liver diseases. Regulatory context from FDA (FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)) supports the near-term read. Assessment grounded in 9 ranked evidence items (8 high-relevance).
Strategic Assessment
Successful outcomes could enhance Ipsen's portfolio in hepatology and provide a new treatment option for PSC, influencing market dynamics. The strongest clinical anchor is A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis (ClinicalTrials.gov), sub-indication match (rare disease); entity match (ipsen). In rare disease, 7 regulatory and 0 competitive items passed relevance filtering for Ipsen.
Competitive Pressure
The most relevant competitive pressure comes from This trial positions Ipsen in the rare disease space, potentially addressing an unmet need in PSC treatment, which may impact competitors focusing on liver diseases..
Regulatory Outlook
Regulatory risk is concentrated around FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG) (FDA). Sub-indication match (rare disease); Regulatory pathway relevance (nda). The trial's outcomes will be critical for regulatory approval, influencing the labeling and market entry of elafibranor as a treatment for PSC.
Key Risks
- Elevated medium regulatory exposure for Ipsen could delay market entry or constrain labeling if agency review intensifies.
Key Opportunities
- If successful, elafibranor could capture market share in the PSC treatment space, potentially leading to increased revenues for Ipsen and altering competitive dynamics.
- Successful outcomes could enhance Ipsen's portfolio in hepatology and provide a new treatment option for PSC, influencing market dynamics.
What Would Change This Assessment
- This becomes more urgent if Monitor trial progress, patient recruitment rates, and interim results over the next five years.
- Timeline shift beyond mid term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceLessons Learned from our Roundtable with Rare Disease Advocates
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
ClinicalTrials.govhigh relevance
Sub-indication match (rare disease); Entity match (ipsen)
FDA document
View sourceFunctional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN
ClinicalTrials.govmedium relevance
Sub-indication match (rare disease)
FDA document
View sourceKHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEVERO Drug-coated Balloon (DCB) Randomized Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceUse of Custom-Made Acrylic Palatal Stent to Minimize Donor Site Morbidity After Suture-Free Epithelialized Gingival Graft Harvesting: A Randomized Clinical Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceTopical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
No evidence in this category.
The Effect of Moxibustion at the Dazhui Point on Hypothermia and Maternal Comfort During Cesarean Delivery: A Randomized Controlled Trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEfficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceAmino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceElevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceOral self-assembly nanoemulsion drives in vivo hepatic stellate cell-targeting drug delivery in liver fibrosis.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Related Signals
Related Regulatory Precedents
FDA
Guidance Documents for Rare Disease Drug Development
SourceFDA
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
Application ANDA075499. Sponsor: APOTEX. Submission status: AP. Submission type: SUPPL. Active ingredients: BUTORPHANOL TARTRATE.
SourceFDA
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
Application ANDA211484. Sponsor: ACERTIS PHARMS. Submission status: AP. Submission type: SUPPL. Active ingredients: LEVORPHANOL TARTRATE.
SourceFDA
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
Application ANDA075824. Sponsor: HIKMA. Submission status: AP. Submission type: SUPPL. Active ingredients: BUTORPHANOL TARTRATE.
SourceFDA
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
Application ANDA074278. Sponsor: HIKMA. Submission status: AP. Submission type: SUPPL. Active ingredients: LEVORPHANOL TARTRATE.
Source